Figure 4 . Cytotoxicity activity of empty unmodified and
modified VLPs on 4T1 breast tumor mouse cell line model, and 293T
healthy embryonic kidney human cells. Two-way RM ANOVA
(p<0.001). *** Significative difference between the two
preparations at the same concentration. ‡ Significative difference with
the control.
The same cytotoxicity experiments were performed with GOx-containing
nanoreactors (Figs. 5 and 6). The results were expressed based on both
GOx content and nanoreactor GOx activity. These two forms to express the
treatment doses are due because the protein content of the two
preparations is significantly different, and if the GOx content is
similar in capsid base the enzymatic activity changes when the
nanoreactor is covered with HAS (Table 1). On the 4T1 breast tumor
cells, the LD50 values were 0.04 µg GOx/mL for VLP-GOx
and around 0.1 µg GOx/mL for VLP-GOx@HSA, and no metabolic activity was
detected at 1 µg GOx/mL for both preparations (Fig. 5a). The 4T1 tumor
cells showed an LD50 at around 1 mU of GOx activity per
mL of cell culture, and no metabolic activity at around 10 mU/mL in both
preparations (Fig. 5b).